Neurofibroma of the esophagus

Summary

Neurofibroma of the esophagus (MONDO:0004837) is a disease. A subtype of neurofibroma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neurofibroma of the esophagus
Mondo ID	MONDO:0004837
DOID	DOID:961
NCIT	C5704
UMLS	C1333463
MedGen	232164
GARD	0024117
Anatomy (UBERON)	UBERON:0001043
Is cancer (heuristic)	no

Also known as: esophageal neurofibroma · esophagus neurofibroma · neurofibroma of esophagus · neurofibroma of oesophagus · neurofibroma of the esophagus · oesophagus neurofibroma

Disease family

This is a subtype of neurofibroma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral nervous system neoplasm › nerve sheath neoplasm › neurofibroma › neurofibroma of the esophagus

Related subtypes (10): mediastinum neurofibroma, neurofibroma of spinal cord, Pacinian tumor, neurofibrosarcoma, epithelioid neurofibroma, neurofibroma of gallbladder, plexiform neurofibroma, cellular neurofibroma, atypical neurofibroma, neurofibroma of the heart

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.